pirenzepine and Dizzyness
pirenzepine has been researched along with Dizzyness in 2 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Beasley, CM | 1 |
Tollefson, GD | 1 |
Tran, PV | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in Body Mass Index (BMI)
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
Intervention | kg/m^2 (Mean) |
---|---|
Aripiprazole | -0.4 |
Placebo | 0.3 |
Change From Baseline in Fasting Total Cholesterol
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
Intervention | mg/dL (Mean) |
---|---|
Aripiprazole | -3 |
Placebo | 9 |
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
Intervention | mg/dL (Mean) |
---|---|
Aripiprazole | 0.4 |
Placebo | 0.6 |
Change From Baseline in Low-density Lipoprotein (LDL)
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
Intervention | mg/dL (Mean) |
---|---|
Aripiprazole | -0.2 |
Placebo | 3.1 |
Change From Baseline in Triglycerides
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
Intervention | mg/dL (Mean) |
---|---|
Aripiprazole | -51.7 |
Placebo | 47.6 |
Change From Baseline in Waist-hip Ratio (WHR)
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
Intervention | cm (Mean) |
---|---|
Aripiprazole | 0.0 |
Placebo | 0.0 |
Change From Baseline in Weight (Lbs)
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
Intervention | lbs (Mean) |
---|---|
Aripiprazole | -2.9 |
Placebo | 2.1 |
Reviews
1 review available for pirenzepine and Dizzyness
Article | Year |
---|---|
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
Trials
1 trial available for pirenzepine and Dizzyness
Article | Year |
---|---|
Olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Constipation; Costs and Cost Analysis; Dizziness; Dose-Respon | 1997 |